Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE ELMAM : revenue, balance sheet and financial ratios

SELARL PHARMACIE ELMAM is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in BOIS-COLOMBES (92270), this company of category PME shows in 2021 a net income positive of 332 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE ELMAM (SIREN 819668773)
Indicator 2021 2020 2019
Revenue N/C N/C N/C
Net income 332 254 € 168 170 € 137 778 €
EBITDA N/C N/C N/C
Net margin N/C N/C N/C

Revenue and income statement

In 2021, SELARL PHARMACIE ELMAM generates positive net income of 332 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2021: 138 k€ -> 332 k€.

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

332 254 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 74%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 47%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

74.026%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

46.642%

Asset age ratio (2021) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

25.1%

Solvency indicators evolution
SELARL PHARMACIE ELMAM

Sector positioning

Debt ratio
74.03 2021
2019
2020
2021
Q1: 29.03
Med: 85.54
Q3: 208.44
Good -28 pts over 3 years

In 2021, the debt ratio of SELARL PHARMACIE ELMAM (74.03) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
46.64% 2021
2019
2020
2021
Q1: 25.88%
Med: 44.4%
Q3: 64.18%
Good +25 pts over 3 years

In 2021, the financial autonomy of SELARL PHARMACIE ELMAM (46.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 273.25. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

273.248

Liquidity indicators evolution
SELARL PHARMACIE ELMAM

Sector positioning

Liquidity ratio
273.25 2021
2019
2020
2021
Q1: 139.19
Med: 190.69
Q3: 259.61
Excellent +13 pts over 3 years

In 2021, the liquidity ratio of SELARL PHARMACIE ELMAM (273.25) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 196 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 800 days. Excellent situation: suppliers finance 604 days of the operating cycle (retail model).

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

196 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

800 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE ELMAM

Positioning of SELARL PHARMACIE ELMAM in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2021, the value of SELARL PHARMACIE ELMAM is estimated at 3 811 091 € (range 2 450 550€ - 5 886 938€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2021
220 transactions
2450k€ 3811k€ 5886k€
3 811 091 € Range: 2 450 550€ - 5 886 938€
NAF 5 année 2021

Valuation method used

Net Income Multiple
332 254 € × 11.5x = 3 811 092 €
Range: 2 450 551€ - 5 886 939€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE ELMAM with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE ELMAM

What is the revenue of SELARL PHARMACIE ELMAM ?

The revenue of SELARL PHARMACIE ELMAM is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE ELMAM profitable?

Yes, SELARL PHARMACIE ELMAM generated a net profit of 332 k€ in 2021.

Where is the headquarters of SELARL PHARMACIE ELMAM ?

The headquarters of SELARL PHARMACIE ELMAM is located in BOIS-COLOMBES (92270), in the department Hauts-de-Seine.

Where to find the tax return of SELARL PHARMACIE ELMAM ?

The tax return of SELARL PHARMACIE ELMAM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE ELMAM operate?

SELARL PHARMACIE ELMAM operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.